Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Keywords

ReactogenicityImmunogenicityMedicineVaccinationNeutralizationVirologyPlaque reduction neutralization testVaccination scheduleImmunologyCoronavirusRandomized controlled trialInternal medicineAntibodyCoronavirus disease 2019 (COVID-19)Immunization

Affiliated Institutions

Related Publications

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Chien‐Te K. Tseng , Elena Sbrana , Naoko Iwata‐Yoshikawa +5 more

These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type i...

2012 PLoS ONE 604 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design

Yuxian He , Jingjing Li , Susanne Heck +2 more

ABSTRACT The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a majo...

2006 Journal of Virology 135 citations

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp , Nianshuang Wang , Kizzmekia S. Corbett +5 more

The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycopr...

2020 Science 9579 citations

Publication Info

Year: 2020
Type: article
Volume: 396
Issue: 10249
Pages: 467-478
Citations: 2590
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2590

OpenAlex

Cite This

APA Style

                            
                                
                                    Pedro M. Folegatti, 
                                
                                    Katie Ewer, 
                                
                                    Parvinder K. Aley
                                
                                et al.
                            
                            (2020). 
                            Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. 
                            The Lancet
                            , 396
                            (10249)
                            , 467-478.
                            https://doi.org/10.1016/s0140-6736(20)31604-4
                        

Identifiers

DOI: 10.1016/s0140-6736(20)31604-4